Biomarker ID | 884 |
PMID | 22371711 |
Year | 2012 |
Biomarker | ANRIL; H19; PCA3; MALAT1; PCGEM1; PTENP1 |
Biomarker Basis | Expression Based |
Biomolecule | LncRNA |
Source | Tissue |
Subjects | Humans |
Regulation | Differentially expressed (Median Fold Change): [ANRIL (MFD: 1.33 fold); H19 (MFD: -1.12 fold); PCA3 (MFD: -3.44 fold); MALAT1 (MFD: -2.63 fold); PCGEM1 (MFD: -4 fold); PTENP1 (MFD: 1.50 fold);] |
Odds Ratio/Hazard Ratio/Relative Risk | NA |
Effect on Pathways | NA |
Experiment | Metastatic Vs Primary |
Type of Biomarker | Diagnostic |
Cohort | 131 primary prostate cancer, 29 normal adjacent, and 19 metastatic specimens were downloaded from GEO Omnibus at GSE21034. (Dataset was: Memorial Sloan–Kettering Cancer CenterProstate Oncogenome Project) |
Senstivity | NA |
Specificity | NA |
AUC | NA |
Accuracy | NA |
Level Of Significance | p<0.04 |
Method Used | NA |
Clinical | No |
Remarks | NA |
Clinical Trial Number | NA |
Degree Of Validity | Validated on independent patient dataset |
Technical Name | CDKN2B-AS1, H19, PCA3, MALAT1, PCGEM1, PTENP1 |